Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Marco Ruella, ASH 2021: Resistance Mechanisms to CAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (PART ONE)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 14th 2021

Dr Marco Ruella (University of Pennsylvania, Philadelphia, PA, USA) discusses his presentation at the 63rd ASH Annual Meeting & Exposition on resistance mechanisms to CAR-T cells in patients with B-cell acute lymphoblastic leukemia. (PART ONE)

Questions
1. What has been the impact of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with B-cell acute lymphoblastic leukemia (ALL)? 00:20-02:30
2. What is the incidence of relapse after CAR-T cell therapy in this patient population? 02:30-03:50

Speaker Disclosure: Marco Ruella discloses research support from Abclon, nanoString and Beckman-Coulter; advisory board membership from Abclon, Bayer, CART Tech, UPenn (partly licensed to Novartis), Tmunity, viTToria biotherapeutics, GSK and Sana; consultancy from nanoString and BMS and is the scientific founder of viTToria biotherapeutics.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 63rd ASH Annual Meeting & Exposition

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup